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Glycogen storage disease type III is an autosomal recessive disease characterized by a deﬁciency in the glycogen 
debranching enzyme, encoded by AGL. Essential features of this disease are hepatomegaly, hypoglycemia, hyper-
lipidemia, and growth retardation. Progressive skeletal myopathy, neuropathy, and/or cardiomyopathy become 
prominent in adults. Currently, there is no available cure. We generated an Agl knockout mouse model by dele-
tion of the carboxy terminus of the protein, including the carboxy end of the glucosidase domain and the 
glycogen-binding domain. Agl knockout mice presented serious hepatomegaly, but we did not observe signs of 
cirrhosis or adenomas. In affected tissues, glycogen storage was higher than in wild-type mice, even in the central 
nervous system which has never been tested in GSDIII patients. The biochemical ﬁndings were in accordance 
with histological data, which clearly documented tissue impairment due to glycogen accumulation. Indeed, elec-
tron microscopy revealed the disruption of contractile units due to glycogen inﬁltrations. Furthermore, adult Agl 
knockout animals appeared less prompt to move, and they exhibited kyphosis. Three-mo-old Agl knockout mice 
could not run, and adult mice showed exercise intolerance. In addition, older affected animals exhibited an accel-
erated respiratory rate even at basal conditions. This observation was correlated with severe glycogen accumu-
lation in the diaphragm. Diffuse glycogen deposition was observed in the tongues of affected mice. Our results 
demonstrate that this Agl knockout mouse is a reliable model for human glycogenosis type III, as it recapitulates 
the essential phenotypic features of the disease. 
1. Introduction 
Glycogen storage disease type III (GSDIII; OMIM 232400) is an auto-
somal recessive disease caused by mutations in the AGL gene encoding 
the glycogen debranching enzyme (GDE; NP_000635.2), which cata-
lyzes the degradation of glycogen into glucose, together with glycogen 
phosphorylase. 
In patients with GSDIII, the liver and muscle are the major tissues in-
volved in pathogenesis, as they normally store glycogen as a reserve. In-
deed, most affected individuals lack enzyme activity in both the liver 
and muscle (GSDIIIa); a few (b15%) have only liver involvement 
(GSDIIIb), while even fewer have selective loss of one of the two catalyt-
ic activities, glucosidase (GSDIIIc) and transferase (GSDIIId) [1]. 
According to its clinical presentation, GSDIII is a two-phase disease. In 
infancy and childhood, the main symptoms are hepatomegaly starting 
from a few weeks/months after birth, hypoglycemia, hyperlipidemia, 
and growth delay [2]. These symptoms tend to decrease gradually dur-
ing adolescence, although apparent glycemic control may hide progres-
sive liver ﬁbrosis. Cirrhosis and hepatic adenomas have also been 
reported, leading to hepatic transplantation in some patients [3–6]. In 
GSDIII patients, the onset of myopathy is now believed to occur at an 
earlier age than thought previously [7]; subtle motor delay in children 
also seems to be more frequent than previously noted. In children, the 
neuromuscular manifestations are hypotonia and mild weakness. In 
adults, myopathy is widespread (70% of patients) from the third or 
forth decade of life [8] and manifests as weakness in the trunk and prox-
imal and distal muscles, with diminished grip strength and a decreased 
ability to jump and walk for extended times. Moreover, different mus-
cles may show different degrees of involvement [9]. A further feature 
of myopathy is atrophy related to neuropathy (glycogen accumulation 
in peripheral nerves) and neuropathic features revealed by electromy-
ography (EMG). Histological samples show storage of nonmembrane- 
bound glycogen vacuoles in the subsarcolemmal region and deep 
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within the muscle ﬁbers; these vacuoles can displace and ultimately re-
place the other cell constituents. Asymptomatic cardiomyopathy may 
be present as left ventricular hypertrophy in at least 50% of patients; 
half of these may have evolving symptoms that eventually worsen to se-
vere cardiomyopathy [10,11]. 
Like other forms of glycogenosis, except for type II, treatment for pa-
tients with GSDIII seeks to control symptoms, and patients follow a suit-
able dietary regimen. At present, there are no ﬁxed recommendations 
regarding regular exercise. This may be related to both a lack of contin-
uous monitoring over time of strength and endurance and a lack of ap-
propriate testing of affected individuals. 
Animal disease models that replicate the major symptoms of a dis-
ease are essential to understand the disease pathogenesis and to test 
new drugs and therapies. Based on observations that a missense [12, 
13] or frameshift [14] mutation in the AGL glycogen-binding domain is 
enough to cause the total absence of enzyme activity, we deleted the re-
gion spanning exons 32–34 to create a constitutive knockout (KO) 
mouse as a disease model for GSDIII. The Agl-KO mouse presented 
here showed a complete absence of protein and a lack of enzymatic ac-
tivity. Most importantly, it reproduced the major features of GSDIII; 
namely, glycogen accumulation in the liver and muscle (and thus hepa-
tomegaly and muscle impairment), indicating that it is a reliable model 
for this disorder. In addition, our data highlighted aspects poorly ex-
plored previously in GSDIII patients such as central nervous system in-
volvement and respiratory function. 
2. Materials and methods 
2.1. Animal studies 
All procedures were approved by the Experimentation Committee of 
the University of Milan and were carried out in accordance with Italian 
guidelines for the care and use of laboratory animals. All mice were 
maintained in temperature- and humidity-controlled conditions, 
allowed free access to a standard diet of chow and water, and main-
tained on a 12:12 h light–dark cycle under speciﬁc pathogen-free 
conditions. 
2.2. Generation of a constitutive Agl-KO mouse model 
The KO mouse model was generated by genOway (Lyon, France). 
Brieﬂy, a Neo cassette was introduced into Agl by homologous recombi-
nation in C57BL/6J embryonic stem (ES) cells, deleting exons 32–34 
(the last 114 amino acids). ES cells were injected into C57BL/6J blasto-
cysts, which were implanted into pseudopregnant females and allowed 
to develop to term. Southern blot analyses were performed to conﬁrm 
the presence of the recombinant allele in females that resulted from 
this breeding. Breeders, generated by mating these heterozygotes with 
C57BL/6J animals, were then mated to produce the null animals. 
2.3. Newborn genotyping 
Genomic DNA was extracted from mouse tails with 50 mM NaOH at 
100 °C for 10 min and neutralized with 3 M Tris–HCl pH 8. To determine 
the pattern of inheritance, two screening PCRs were designed. PCR 1 
allowed for detection of Agl recombined KO alleles and was performed 
with a primer hybridizing downstream of the targeting vector homolo-
gy sequence, with the other primer located in the Neo cassette. The ex-
pected recombined product was 1.9 kb in heterozygous and Agl-KO 
mice, whereas wild-type (WT) DNA yielded no ampliﬁcation products. 
PCR 2 was performed with a primer hybridizing in the vector 3′ homol-
ogy arm and a primer in a region deleted in the KO locus (exon 34). The 
expected endogenous product was 0.4 kb in WT and heterozygous mice. 
For both PCR assays, 0.2 U of Platinum Taq Polymerase (Invitrogen, 
Carlsbad, CA, USA) was used in a 30 μL reaction and ampliﬁcation prod- 
ucts were run on a 1.5% agarose gel. 
2.4. Biochemical assays 
Mice were sacriﬁced by cervical dislocation. Tissues for analysis 
were then rapidly excised, frozen in liquid nitrogen, and stored at 
−80 °C. 
2.4.1. Western blot analysis 
Homogenized extracts (20 μg of protein) from the skeletal muscle, 
brain, liver, and heart tissue of WT, heterozygous, and KO mice were an-
alyzed. The protein extract was separated on a 6% acrylamide gel and 
electrophoretically transferred to a nitrocellulose membrane. The blots 
were probed for expression of GDE with rabbit polyclonal antibody 
(1:2200; Agrisera, Vannas, Sweden) and peroxidase-conjugated sec-
ondary antibody. The signal was detected with an ECL detection kit 
(Amersham-GE Healthcare, Little Chalfont, UK). 
2.4.2. GDE activity 
Debrancher enzyme activity was measured in frozen muscle and 
liver tissue with an indirect assay based on stimulation of the incorpora-
tion of radioactive glucose into glycogen [15]. Enzyme activity was 
expressed as picomoles of glucose incorporated into glycogen/min/mg 
protein. 
2.4.3. Determination of glycogen absorption spectrum and content 
The absorption spectrum of glycogen was evaluated by the glycogen– 
iodine complex method [16]. Amyloglucosidase digestion of ethanol-
precipitated glycogen was used to assess the glycogen content from 
the skeletal muscle, liver, heart, and brain (20–70 mg of tissue) samples, 
as previously described [17]. We increased the amyloglucosidase work-
ing concentration up to 0.6 mg/ml. After amyloglucosidase digestion, we 
estimated glucose concentration in diluted samples with the Glucose 
Hexokinase Kit (Greiner Diagnostic, Bahlingen, Germany). Absorbance 
was read at 340 nm after a 5 min incubation at 37 °C. 
2.5. Laboratory testing 
2.5.1. Glycemia 
Glycemia values were measured with blood glucose test strips in a 
FreeStyle Optium H system (Abbott Diabetes Care, Witney, UK). Tail 
vein blood samples were collected from 7- and 8-mo-old mice. 
2.5.2. Serum biochemistry 
Blood samples were collected by intracardiac puncture after anes-
thesia. This procedure was followed by euthanasia. Blood was gathered 
in tubes and centrifuged at 3000 rpm for 5 min to collect serum. Serum 
was frozen and sent to Charles River Laboratories to be analyzed. 
2.6. Histology and electron microscopy 
For light microscopy studies, fresh organs and tissues were immedi-
ately frozen in isopentane, cooled in liquid nitrogen, and then processed 
according to standard methods [18]. Routine stains with and without 
prior diastase digestion were performed with hematoxylin and eosin, 
Gomori Trichrome (TG), Masson, and periodic acid–Schiff (PAS). 
Semithin sections, stained with toluidine blue, were examined by light 
microscopy. For ultrastructural examination, muscle samples were 
ﬁxed in 2.5% glutaraldehyde (pH 7.4) and postﬁxed in 2% osmium te-
troxide. After dehydration in a graded series of ethanol concentrations, 
the samples were embedded in Spurr's resin. Finally, ultrathin sections 
were examined with a Zeiss EM109 transmission electron microscope 
[18]. 
2.7. Evaluation of muscle performance 
All animals were tested in the morning during the light phase of the 
light–dark cycle. Isolated mice and pregnant females were excluded. 
2.7.1. Hind print test 
The footprint test was used to compare the gait of the Agl-KO mice 
with that of their WT counterparts. For the hind print test, nontoxic 
paint was applied to the inside of the hind paws of the mice. They 
were then placed on a paper sheet at the beginning of a corridor 
(10 cm × 60 cm) and allowed to complete the maximum length 
achievable. 
2.7.2. Treadmill test 
Mice were trained for 2 days on a single lane treadmill (Panlab 
LE8708; Panlab Harvard Apparatus, Cornellà, Spain) supplied with an 
electriﬁed grid to provide motivation with a mild shock (0.2 mA). The 
incline was 5° with an accelerating speed from 5 to 15 cm/s during 
15 min. Mice were administered two different experimental conditions 
after a warming run of 3 min on a speed belt at 10 cm/s. For the ﬁrst 
protocol, animals were run at 30 cm/s for 5 min. For the second, mice 
were tested at a constant belt speed of 15 cm/s and allowed to cover a 
maximum distance of 350 m. For both experiments, the incline was 
5°. The tests were interrupted when the mouse was unable to remain 
on the belt. 
2.7.3. Rota-rod test 
The Rota-rod (Accelerating Model; Ugo Basile, Varese, Italy) was 
used to measure forelimb and hindlimb motor coordination and bal-
ance. Before the test, mice were trained by undergoing one trial per 
day for two consecutive days. For the rota-rod test, mice were placed 
on a rotating rod accelerating from 5 to 20 rpm in 5 min. Each mouse 
was tested twice; the best performance from each mouse was consid-
ered, and the results were expressed as mean ± standard deviation 
(SD). 
2.8. Statistical analysis 
The Kaplan–Meier estimator was employed to plot lifetime data and 
calculate the survival function. Statistical signiﬁcance was estimated 
with Student's t-test to compare experimental groups. Error bars denote 
SD. A P value of b0.05 was considered statistically signiﬁcant. 
3. Results 
3.1. Generation and general features of Agl-KO mice 
Agl-KO mice were created by deletion of the carboxy terminus of 
GDE, including the glucosidase and glycogen-binding domains (Fig. 1). 
The affected mice were viable, but presented higher mortality in adult-
hood than WT mice (Fig. 2A), whereas heterozygotes were viable and 
fertile and did not show any differences compared to WT animals. Agl-
KO mice did not differ considerably in size or appearance from their 
WT and heterozygous littermates at birth or during development 
(Fig. 2B). 
Western blot analysis of the skeletal muscle, heart, liver, and brain tis-
sue conﬁrmed the total absence of GDE in all tissues from Agl-KO mice 
(Fig. 2C). In heterozygotes, GDE protein was signiﬁcantly reduced com-
pared to WT. As expected, GDE activity was almost null in Agl-KO mice 
(skeletal muscle, 2.30 ± 1.25 and liver, 5.58 ± 1.65 pmol glucose/min/ 
mg protein; n = 3) compared to WT mice (skeletal muscle, 216.25 ± 
36.40 and liver, 37.23 ± 1.45 pmol glucose/min/mg protein; n = 3). Het-
erozygotes exhibited lower GDE activity (skeletal muscle, 134.23± 13.51 
and liver, 23.37 ± 6.34 pmol glucose/min/mg protein; n = 3) than WT 
mice (Table 1). 
Upon autopsy, macroscopic examination revealed that Agl-KO livers 
were enlarged and dark red in color compared to WT liver (Fig. 2E). We 
did not observe nodules indicating cirrhosis or adenomas, even at ad-
vanced age (18 mo; n = 1). Livers from 3-mo-old Agl-KO mice had in-
creased to over 9% of total body weight and up to 11% in mice aged 
12 mo, whereas the liver comprised between 5 and 6% of total body 
weight in WT mice (n = 4 for each group) (Fig. 2D). No differences 
were observed in the dimensions or percent of total body weight of 
the heart between Agl-KO and WT mice at any age (n = 4 for each 
group) (Suppl. Fig. 1). 
3.2. Glycogen content 
Absorbance spectrum measurements of liver glycogen revealed an 
absence of the 460-nm peak, as observed in GSDIII patients; this indi- 
cates an abnormal glycogen structure (i.e., phosphorylase-limit dextrin) 
Fig. 1. Targeted disruption of the Agl gene. Schematic representation of the targeting vector and the homologous recombination product. 
(Fig. 3A). Differences in peak width accounted for different glycogen 
amounts among samples. 
We next assessed glycogen content in the skeletal muscle, liver, 
heart, and brain tissue from adult Agl-KO, heterozygous, and WT mice 
(n = 5 for each group, except for the heart: n = 3). All affected tissues 
contained substantial amounts of glycogen (skeletal muscle, 4.5 ± 0.9; 
liver, 7.7 ± 0.6; heart, 2.1 ± 0.3; and brain, 0.2 ± 0.04 g/100 g tissue), 
which were higher than in heterozygous (skeletal muscle, 0.3 ± 0.05; 
liver, 2.7 ± 0.7; heart, 0.01 ± 0.01; and brain, 0.01 ± 0.01 g/100 g tis-
sue) and WT (skeletal muscle, 0.2 ± 0.07; liver, 2.9 ± 1.1; and heart, 
0.08 ± 0.0.07 g/100 g tissue; brain, glycogen not detectable) tissues 
(Fig. 3B). All P values b0.0005. 
3.3. Glycemia 
Adult fed Agl-KO mice had basal blood glucose values signiﬁ-
cantly lower (92 ± 9 mg/dl; n = 5) than heterozygous (132 ± 
9 mg/dl; n = 5) and WT (164 ± 18 mg/dl; n = 5) mice (Agl-KO 
vs. WT mice, P b 0.0001) (Fig. 4). After 16 h of fasting, glycemia 
was considerably reduced in Agl-KO mice (59 ± 8 mg/dl; n = 4) 
compared to heterozygous and WT mice (111 ± 17 mg/dl and 
100 ± 21 mg/dl, respectively; n = 4 for each) (Fig. 4A). 
3.4. Serum biochemistry 
Serum biochemistry (Fig. 4B) in Agl-KO fed mice revealed high levels 
(1.8–12.6 fold) of ALT, AST and ALP in 3-mo-old (AST 223 ± 126 U/l; ALT 
95± 55 U/l; ALP 96± 10 U/l) and in 12-mo-old mice (AST 469± 105 U/l; 
ALT 146 ± 44 U/l; ALP 91 ± 23 U/l) compared to WT mice (3-mo: AST 
Fig. 2. Characterization of Agl-KO mice. A) Kaplan–Meier curve. Lines representing survival of heterozygous and WT mice are superimposed (n =10 for each group). B) Photograph of 4-d-
old mice. No appreciable differences in general appearance were noted among genotypes. C) Western blot demonstrating the absence of GDE protein in all tissues from Agl-KO mice. 
D) Liver weight expressed as percentage of whole body weight in WT and Agl-KO mice at 3 and 12 mo of age (n = 4 for each group). E) Agl-KO liver appeared enlarged and dark red 
in color compared to WT liver. Signs of cirrhosis or adenomas were not observed. ***P b 0.0001. Means ± SD are shown. 
Table 1 
GDE activity in skeletal muscle and liver. 
GDE activity 
pmol glucose/min/mg protein 
+/+ +/− −/− 
Skeletal muscle 
(n = 3) 216.25 ± 36.40 134.23 ± 13.51 2.30 ± 1.25 
Liver 
(n = 3) 37.23 ± 1.45 23.37 ± 6.34 5.58 ± 1.65 
64± 35 U/l; ALT 46± 16 U/l; ALP 41 ± 9 U/l; 12-mo: AST 37± 5 U/l; ALT 
24 ± 5 U/l; ALP 49 ± 14 U/l). Liver transaminases increased with age, 
whereas ALP remained steadily higher. Examination of serum triglycer-
ides (TRIG) and total cholesterol (CHOL) did not show any difference be-
tween Agl-KO (3-mo: TRIG 79 ± 35 mg/dl; CHOL 81 ± 9 mg/dl; 12-mo: 
TRIG 86 ± 31 mg/dl; CHOL 83 ± 13 mg/dl) and WT mice (3-mo: TRIG 
100 ± 20 mg/dl; CHOL 84 ± 7 mg/dl; 12-mo: TRIG 74 ± 37 mg/dl; 
CHOL 84 ± 8 mg/dl) not even at old ages. Serum CK was signiﬁcantly 
higher in Agl-KO (3-mo: 247 ± 57 mg/dl; 12-mo: 272 ± 53) than in 
WT mice (3-mo: 87 ± 6 mg/dl; 12-mo: 43 ± 11 mg/dl) at both young 
and old ages (P b 0.05). 
3.5. Histology and electron microscopy 
We performed a detailed histological examination of the liver, mus-
cle, heart, brain, cerebellum and sciatic nerve from 4-, 8-, 12-, and 18-
mo-old mice. Signiﬁcant glycogen accumulation was detected in skele-
tal muscle (vastus, Fig. 5B–E), and in hepatocytes from Agl-KO mice at 
all ages (Fig. 5G–L), while heterozygous mice did not show any changes 
compared to their respective WT littermates (data not shown). In Agl-
KO mice, hepatocytes appeared enlarged due to glycogen deposition. 
However, the liver did not exhibit ﬁbrosis (Fig. 6) even in older mice, 
and there was no evidence of inﬂammation at any age. Glycogen depo-
sition in cardiac tissue was found in Agl-KO mice at all examined ages 
(Fig. 5N–Q). TG analysis revealed that pathological alterations were 
present in all of the muscles tested from Agl-KO mice: vastus, gastrocne-
mius, and diaphragm (Fig. 7). 
Ultrastructural examination (Fig. 8) of skeletal muscle from 4- and 
12-mo-old mice reﬂected the histological ﬁndings that assessed muscle 
damage in Agl-KO mice. In muscle tissue from 4-mo-old affected ani-
mals, we found glycogen granules dispersed among the myoﬁbrils 
(Fig. 8A). In 12-mo-old Agl-KO mice, muscle ﬁbers contained large gly-
cogen collections that were localized both at the subsarcolemmal level 
and at intracytoplasmic sites. Large regions of the sarcoplasm were 
entirely occupied by cytoplasmic glycogen, leading to marked alter-
ations in the muscle architecture (Fig. 8B). 
We did not ﬁnd any morphological alterations in the brain or cere-
bellum with respect to WT mice. However, PAS staining showed a slight 
increase of glycogen content in brain frontal cortex in all Agl-KO mice 
examined (Fig. 9). Furthermore, in cerebellum we observed PAS-
positive glycogen deposits in the granular layer adjacent to the Purkinje 
cell layer (Fig. 9) which increased with age; the highest amounts of gly-
cogen were observed in 18-mo-old Agl-KO mice. 
We analyzed sciatic nerve in 12- and 18-mo-old Agl-KO mice by light 
microscopy. As shown in Supplementary Fig. 2, nerve tissue had a nor-
mal appearance and no glycogen granules were detected. 
Since a recent clinical study observed fatty inﬁltration in the tongue 
musculature in some GSDIII patients [19], we analyzed tongue tissue 
from 4- and 18-mo-old mice. In Agl-KO mice, we found glycogen accu-
mulation, as shown in Supplementary Fig. 3. 
3.6. Evaluation of muscle performance 
Adult Agl-KO mice appeared to be slower than their littermates, and 
the hind print test showed everted paws during walking, even in 3-mo-
old Agl-KO mice, suggesting early muscle involvement (Fig. 10A). To 
further assess muscle performance in young mice, we ﬁrst evaluated 
their ability to run on a treadmill device using a belt speed of 30 cm/s. 
We tested 4 Agl-KO mice and observed signiﬁcant performance variabil-
ity. Indeed, at 2 mo of age, 2 mice were able to run for the maximum 
time established (5 min), whereas 2 mice could only run for a few sec-
onds. The same mice tested at 3 months of age showed a dramatic de-
crease of their performances: those that performed better in the ﬁrst 
test could run just half a minute in the second, whereas the other ones 
were not able to remain on the belt (Fig. 10B). We then tested 9-mo-
old mice (n = 5 for each group). None of the Agl-KO mice were able 
to remain on the belt, whereas WT mice were able to run for 5 min. 
We next assessed the capacity of the mice to perform mild exercise 
for long distances (belt speed of 15 cm/s for 350 m). Under these 
Fig. 3. Glycogen content. A) Absorbance spectrum showing abnormal glycogen structure and content in 4-mo-old Agl-KO mice. B) Histogram depicting increased glycogen content in all 
tissues from Agl-KO mice (n = 5 for each group except the heart n = 3). All of P values b0.0005. Means ± SD are shown. 
conditions, Agl-KO mice were able to remain on the belt and execute the 
test. One of the mice reached 350 m. Agl-KO mice walked for a mean dis-
tance of 228 ± 80 m, while WT mice walked for 350 m (P b 0.05) 
(Fig. 10C). 
Motor coordination was evaluated by Rota-rod test. In an accelerat-
ing test (from 5 to 20 rpm in 5 min), 8-mo-old Agl-KO mice performed 
less well than age-matched controls (P b 0.05; n = 8 for each group). 
Only two out of eight Agl-KO mice were able to complete the test 
(Fig. 10D). 
4. Discussion 
GSDIII is a rare genetic metabolic disorder that mainly affects the 
liver, skeletal muscle and heart. This glycogenosis is incurable, and a 
suitable dietary is the only treatment currently available. Here we de-
scribe a constitutive KO mouse model obtained by deleting the last 
114 amino acids of the debranching enzyme. A natural canine model 
of GSDIII has been reported [14], in which the loss of GDE is caused by 
a deletion of the last 126 amino acids due to a frameshift mutation. An-
other model for GSDIII was published recently by Liu and colleagues 
[20]: a KO mouse generated by disrupting the Agl gene downstream of 
exon 5. 
Viability data collected for our Agl-KO mice suggested a tendency to-
ward a higher mortality within 1 y of age compared to WT mice 
(Fig. 2A). Viability data presented here are similar to those described 
for the other GSDIII KO mouse model. No mortality is reported in 
the dog model. Mortality has never been reported in GSDIII patients [9], 
but large longitudinal studies are lacking. While human diets are 
Fig. 4. Biochemistry detection. A) Blood glucose determination in 7 and 8 mo aged mice. Basal glycemia in Agl-KO mice was signiﬁcantly lower than in heterozygous and WT mice (gray 
bars; n = 5). As expected, after 16 h fasting, blood glucose levels decreased in all genotypes; nevertheless, glucose values were still signiﬁcantly different between Agl-KO and WT mice 
(lined bars; n = 4). ***P b 0.0001, *P b 0.05. B) Serum biochemistry in Agl-KO and WT fed mice at 3 and 12 mo of age. ***P b 0.005, *P b 0.05 Means ± SD are shown. 
modiﬁed to treat GSDIII, for our animal model, no dietary correction 
was provided. In addition, Agl-KO mice exhibited a severe muscle impair-
ment that could prevent the most affected animals from adequately 
feeding. 
No growth delay was ascertained in the affected mice, which is in ac-
cordance with observations in other GSDIII models [20,21], but in con-
trast to a clinical feature frequently reported in patients [22,23]. 
When we examined the liver tissue from mice sacriﬁced at different 
ages, we did not notice signs of cirrhosis or adenomas in the Agl-KO 
mice, even in one 18-mo-old animal. Nevertheless, these mice present-
ed hepatomegaly, and liver parenchyma appeared darker compared to 
WT (Fig. 2D and E). Marked amounts of glycogen storage were observed 
starting at young ages in affected liver cells, which appeared enlarged 
(Figs. 5 and 6). As shown in Fig. 6, there was no evidence of inﬂamma- 
tion or ﬁbrosis in the liver, even in older mice. In both previously 
reported GSDIII animal models, signs of liver ﬁbrosis were described; 
in the curly-coated retrievers, diffuse nodular cirrhosis was also 
observed. 
We observed that basal glycemic values were lower in adult Agl-KO 
mice compared to their WT and heterozygous littermates. The physio-
logical lack of debranching enzyme in this disease leads to reduced glu-
cose levels if no corrections are made to carbohydrate dietary intake. 
Our mouse model was fed a standard diet, and this may explain the 
lower basal levels of glucose in the affected mice. Other experiments 
are needed to elucidate the complex metabolic features underlying 
this pathological condition. 
Serum biochemistry parameters on normally fed Agl-KO mice 
reﬂected the main pathological features found in human patients and 
were in agreement with histological and functional ﬁndings. Hyperlip- 
idemia, which is frequently found in human patients, was not observed 
Fig. 5. PAS staining showing glycogen accumulation in Agl-KO mice. WT mice (A, F, M); 4-mo-old (B, G, N), 8-mo-old (C, H, O), 12-mo-old (D, I, P), and 18-mo-old (E, L, Q) Agl-KO mice. 
Vastus (A–E), liver (F–L), and heart (M–Q). Scale bar: 20 μm. 
Fig. 6. Gomori trichrome and Masson's staining of liver tissue. WT mouse (A); 4-mo-old (B), 8-mo-old (C), 12-mo-old (D) and 18-mo-old Agl-KO mice (E, F). TG staining: A–B–C–D–E. 
Masson's staining: F. Scale bar (A, B, C, D, E): 25 μm. Scale bar (F): 12.5 μm. 
in our animal model (Fig. 4B). Indeed, triglyceride and cholesterol levels 
were normal in both dog and mouse models previously reported [20, 
21]. Serum AST, ALT and ALP were considerably increased in young 
mice and signiﬁcantly higher than WT in older mice (12.6, 6.1 and 1.8 
fold). These data were a further conﬁrmation of liver damage due to 
abnormal glycogen storage clearly demonstrated by histological analy-
sis (Figs. 5 and 6) and correlated with high transaminase levels found 
in GSDIII patients. Similarly, CK levels were signiﬁcantly higher in Agl-
KO mice even at 3 mo of age. Liu and colleagues reported normal CK 
values, whereas GSDIIIa dog showed CK increase beginning at 10 mo 
Fig. 7. Representative light microscopy images showing progressive muscle ﬁber vacuolization. WT mice (A, E, I); 4-mo-old (B, F, L), 12-mo-old (C, G, M), and 18-mo-old (D, H, N) Agl-KO 
mice. Vastus (A–D), gastrocnemius (E–H), and diaphragm (I–N). Scale bar: 20 μm. 
Fig. 8. Ultrastructural analysis. Representative electron microscopic images of 4-mo-old Agl-KO mice (A), 12-mo-old Agl-KO mice (B), 12-mo-old heterozygous mice (C), and WT mice (D). 
In 4-mo-old Agl-KO mice (A), glycogen granules were dispersed among the myoﬁbrils. In 12-mo-old Agl-KO mice (B), large glycogen collections were localized at the subsarcolemmal level 
and at intracytoplasmic sites. Large regions of the sarcoplasm were entirely occupied by cytoplasmic glycogen, leading to marked alterations inmuscle architecture. Scale bars: 1428 nm (A, 
C) and 833 nm (B, D). 
of age. In our model, Agl-KO mice expressed muscle phenotype starting 
at a young age (Fig. 10). In addition, GSDIII patients have been previous-
ly reported to have increased CK levels since the ﬁrst decade of life [24]. 
The glycogen content (Fig. 3B) was signiﬁcantly higher in all of the 
tissues predominantly affected by the disease. Marked glycogen deposi-
tion was noticed in the heart from Agl-KO mice, but these mice did not 
develop ﬁber hypertrophy or ﬁber disarray (Suppl. Fig. 1B). The heart/ 
body weight ratio did not suggest cardiac hypertrophy (Suppl. Fig. 1A). 
We cannot exclude cardiomyopathy, though it was not reported in the 
mouse model by Liu and colleagues who performed echocardiography 
analysis [20]. Left ventricular hypertrophy is common in GSDIII patients, 
although a limited number of patients actually develop symptomatic 
cardiomyopathy [9,10]. 
With respect to musculoskeletal involvement, adult Agl-KO mice 
were less prompt to move and slower than their healthy littermates. 
Furthermore, adult mice exhibited kyphosis. This fact, together with 
the decreased muscular performance and a gait defect (everted paws), 
may be related to the diminished capacity of affected mice to stay coor-
dinated on the Rota-rod device. Postural defects, such as mild lumbar 
lordosis, which presumably occurs to accommodate increased abdomi-
nal girth due to hepatomegaly, have been reported in some adult pa-
tients with GSDIII [9]. 
Muscle tissues of Agl-KO mice showed a dramatic increase in the gly-
cogen amount which was 20-fold higher than in WT muscles (Fig. 3B). 
The biochemical ﬁndings were in accordance with histological data 
(Fig. 5). TG conﬁrmed the progressive alteration of muscle macroscopic 
architecture (Fig. 7), and electron microscopy (Fig. 8) revealed that the 
structure of the functional units was altered due to glycogen inﬁltra-
tions. Indeed, 2- and 3-mo-old mice forced to run at 30 cm/s showed 
early and unexpected muscle impairment. Nine-mo-old Agl-KO mice 
could not run at all. Furthermore, when adult Agl-KO mice were tested 
with mild exercise on the treadmill, their performance was worse 
than healthy mice, although one Agl-KO animal was able to complete 
the exercise (Fig. 10). The exercise intolerance observed in adult Agl-
KO mice is likely due to muscle wasting, but we cannot exclude that it 
may also arise from metabolic derangement, as suggested in a recent 
study by Preisler et al. [25]. These authors diverged from the conven-
tional notion that muscle wasting is primarily responsible for ﬁxed 
weakness and suggested that the muscular symptoms in GSDIII are re-
lated to dynamic exercise; that is, they may be associated with impaired 
muscle glycogenolysis. 
Glycogen accumulation in GSDIIIa dogs produced progressive dam-
age in muscle, with disruption of the contractile apparatus from 
12 mo of age. The mouse model by Liu and colleagues showed signs of 
muscle weakness and decreased muscle strength at 1 y of age associated 
with normal CK values. 
In order to better characterize the localization of glycogen in central 
and peripheral nervous systems in Agl-KO mice, we performed a histo-
logical analysis of brain and cerebellum at different ages. We did not 
ﬁnd any morphological alteration in both tissues with respect to WT 
mice. However, in all Agl-KO mice examined PAS staining showed a 
slight increase of glycogen in brain frontal cortex. In cerebellum, mild 
Fig. 9. Representative light microscopy images showing a light glycogen increase in the brain and cerebellum. WT mice (A, B, C, D); 8-mo-old (E, F, G, H), 12-mo-old (I, L, M, N) and 18-mo-
old Agl-KO mice (O, P, Q, R). Brain (A, B, E, F, I, L, O, P), cerebellum (C, D, G, H, M, N, Q, R). A–E–I–O–C–G–M–Q: Hematoxylin–eosin staining. B–F–L–P–D–H–N–R: PAS staining. Scale bar: 
25 μm. 
PAS-positive glycogen deposits were revealed in the granular layer just 
adjacent to the Purkinje cells, especially evident in 18-mo-old mice 
(Fig. 9). Because the cerebellum is responsible for proper muscle tone 
and equilibrium we hypothesize that defective coordination revealed 
by Rota-rod test might be related to glycogen deposits in granular 
layer. No studies on nervous system have been described on the other 
GSDIII models. Peripheral neuropathy has been reported in few patients 
due to glycogen accumulation in peripheral nerves [26,27]. However, 
morphological alteration due to glycogen storage was not detected in 
sciatic nerve from 12- and 18-mo-old Agl-KO mice (Suppl. Fig. 2). 
As a further pathological feature of our mouse model, we noticed an 
accelerated respiratory rate in older animals compared to heterozygous 
and WT littermates, even at basal conditions. This observation correlat-
ed with the severe glycogen accumulation observed in the diaphragm 
(Fig. 7L–N) of a 12-mo-old mouse with respiratory impairment. Patients 
with generalized myopathy tend to have more severe weakness that 
often affects the respiratory muscles [23,28]. 
Histological analysis of tongue tissue from affected mice revealed 
diffuse glycogen deposition in the intrinsic musculature (Suppl. Fig. 3). 
Inﬁltration of glycogen in the tongue was described in the canine 
model of GSDIII [21] and in some patients, in whom it may be associated 
with speech and language pathology and dysphagia [19]. 
The results presented here regarding our Agl-KO mouse model sug-
gest that it is a reliable model for GSDIII, since it exhibits the essential 
phenotypic features of this disease in humans, such as liver and muscle 
impairment. In our mouse model, marked muscle impairment was 
clearly detectable starting at 2 mo of age, whereas the mouse model de-
scribed by Liu and colleagues seemed to exhibit reduced motor activity 
at 1 y of age. Furthermore, our data indicate a possible and not yet re-
ported involvement of central nervous system that could be worth for 
deep investigation in GSDIII patients. We believe that this model will 
be of use in future studies of GSDIII pathophysiology, as well as for test-
ing new treatments and therapies. 
Supplementary data to this article can be found online at http://dx. 
doi.org/10.1016/j.bbadis.2014.07.029. 
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Fig. 10. Functional assessment of muscle performance. A) Hind print test. 3-mo-old Agl-KO mice showed a gait defect compared to healthy littermates. B) Running test on 2- and 3-mo-old 
mice with speed belt of 30 cm/s. At 3 mo of age running ability was dramatically impaired (Agl-KO n = 4; WT n = 3). C) Treadmill test showed that at low speed (15 cm/s), Agl-KO mice 
were able to run on the belt, although they covered short distances (n = 5). D) In the Rota-rod test, 8-mo-old Agl-KO mice showed less-coordinated movements and were more prompt to 
fall (n = 8). *P b 0.05. Means ± SD are shown. 
 
